The Centers for Medicare & Medicaid Services’ decision to update the Medicare Part D program by allowing plans to adopt a second, preferred specialty tier with lower cost-sharing, has been welcomed by both the Association for Accessible Medicines and its Biosimilars Council.
AAM called the CMS’ proposal, “an important first step to support adoption of biosimilars.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?